BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32552950)

  • 1. [Effect of Modified LMB 89± Rituximab Regimen on Long-Term Benefits for Patients's with Burkitt Lymphoma].
    Tan L; Xie Y; Yang J; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):872-875. PubMed ID: 32552950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical Efficacy and Prognostic Factors of Newly Diagnosed Children[JP] with Burkitt Lymphoma Treated by High-Dose and Short-Course Modified LMB Regimen ± Rituximab].
    Wang BT; Dang HB; Wei YJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):529-534. PubMed ID: 32319391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.
    Fayad L; Thomas D; Romaguera J
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S57-62. PubMed ID: 18284717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long term efficacy of COPADM regimen in the treatment of 20 patients with Burkitt lymphoma].
    Yang D; Wang P; Chen J; Li CX; Zhang Y; Chen XC; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Aug; 39(8):645-649. PubMed ID: 30180465
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
    Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of AIDS-related Burkitt lymphoma: a multi-institution retrospective survey in Japan.
    Kojima Y; Hagiwara S; Uehira T; Ajisawa A; Kitanaka A; Tanuma J; Okada S; Nagai H
    Jpn J Clin Oncol; 2014 Apr; 44(4):318-23. PubMed ID: 24558129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical characteristics and outcomes of 16 Burkitt' s lymphoma with testicular involvement].
    Huang S; Jin L; Yang J; Duan YL; Zhang M; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):768-773. PubMed ID: 27719719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical analysis of a modified LMB89 Group C regimen in the treatment of pediatric high-risk Burkitt lymphoma].
    Zhang M; Jin L; Yang J; Duan YL; Huang S; Zhou CJ; Zhang YH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):633-638. PubMed ID: 31495128
    [No Abstract]   [Full Text] [Related]  

  • 10. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
    Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
    Diviné M; Casassus P; Koscielny S; Bosq J; Sebban C; Le Maignan C; Stamattoulas A; Dupriez B; Raphaël M; Pico JL; Ribrag V; ;
    Ann Oncol; 2005 Dec; 16(12):1928-35. PubMed ID: 16284057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment outcomes of adult Burkitt lymphoma: results with a modified LMB protocol in Brazil and feasibility of outpatient administration.
    Silva Junior WFD; Rosa LID; Belesso M; Lage LAPC; Rocha V; Pereira J
    J Chemother; 2018; 30(6-8):375-379. PubMed ID: 30663548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma].
    Zhang M; Wu P; Duan YL; Jin L; Yang J; Huang S; Liu Y; Hu B; Zhai XW; Wang HS; Fu Y; Li F; Yang XM; Liu AS; Qin S; Yuan XJ; Dong YS; Liu W; Zhou JW; Zhang LP; Jia YP; Wang J; Qu LJ; Dai YP; Guan GT; Sun LR; Jiang J; Liu R; Jin RM; Wang ZJ; Wang XG; Zhang BX; Chen KL; Zhuang SQ; Zhang J; Zhou CJ; Gao ZF; Zheng MC; Zhang Y
    Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1011-1018. PubMed ID: 36207847
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse.
    Samra B; Khoury JD; Morita K; Ravandi F; Richard-Carpentier G; Short NJ; El Hussein S; Thompson P; Jain N; Kantarjian H; Jabbour E
    Blood Adv; 2021 Oct; 5(20):3913-3918. PubMed ID: 34464974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and Safety of Intensive Maintenance Chemotherapy Regimen for Treatment of Children and Adolescents with Lymphoblastic Lymphoma for Stage III-IV].
    Liu YF; Liu SW; Sun XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):524-528. PubMed ID: 32319390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
    Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
    Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma.
    Chen M; Wang Z; Fang X; Yao Y; Ren Q; Chen Z; Tian Y; Pan F; Li X; Li Z; Cai Q; Huang H; Lin T
    Cancer Biol Med; 2021 Aug; 18(3):833-40. PubMed ID: 35979854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
    Cortes J; Thomas D; Rios A; Koller C; O'Brien S; Jeha S; Faderl S; Kantarjian H
    Cancer; 2002 Mar; 94(5):1492-9. PubMed ID: 11920506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.